Register online | Log in | My Prescrire

Issue contents

• Current issue
• Last 12 issues
• All issues

Topics

• Annual Prescrire Awards
• Advancing healthcare policy
• Positions
• Mediator° - the criminal trial
• Drugs to avoid: 2024 update
• Spotlight

About Prescrire

• Editorial policies
• How we work
• AMP: non-profit
• Financing
• No conflicts of interest
• Where to find us
• About Prescrire International
• Citations in other journals
• Prescrire events
• A global network

Offers

• Subscribe or renew my subscription
• Solidarity Subscription Rate
• Subscribers: register online
• Prescrire's other products
• Free Special Edition
• Sign up to receive the newsletter

english.prescrire.org

Prescrire's other websites

Prescrire.org Formations Prescrire Prescrire Campus Éviter l'Évitable

In Prescrire's Spotlight

European Commission: lobbyists block nutritional labelling  Editorial  Nutri-Score is a labelling system for food and beverages that informs consumers about the product's nutritional quality. The label is displayed on food packaging on a voluntary basis by manufacturers, and by supermarket chains on their own-brand products. Full article available for download (free) 1 July 2024

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Dupilumab (Dupixent°) in prurigo nodularis  Marketing Authorisations   Dupilumab, an immunosuppressive monoclonal antibody directed against interleukin-4 and interleukin-13 receptors, has been authorised in the European Union for the treatment of prurigo nodularis, a condition that can greatly impair patients' quality of life. Full article available for download by subscribers 1 July 2024

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Netarsudil (Rhokiinsa°) or netarsudil + latanoprost (Roclanda°) in chronic glaucoma: not acceptable  Marketing Authorisations   Eye drops containing netarsudil, alone or combined with latanoprost, have been authorised in the European Union to lower intraocular pressure in adults with chronic open-angle glaucoma or ocular hypertension. Netarsudil exposes patients to a higher risk of adverse effects than the first-choice ocular antihypertensive drugs, timolol or latanoprost, while offering no demonstrated gain in efficacy. Full article available for download by subscribers 1 July 2024

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Zanubrutinib (Brukinsa°) in certain haematological malignancies  Marketing Authorisations   Zanubrutinib has been authorised for use in chronic lymphocytic leukaemia and Waldenström macroglobulinaemia (as has ibrutinib), and in certain patients with relapsed or refractory marginal zone lymphoma. Does zanubrutinib extend survival compared with the other options used in these situations, in particular ibrutinib? Does it have fewer or less severe adverse effects than ibrutinib? Full article available for download by subscribers 1 July 2024

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Methadone: an analysis of adverse effects reported in France  Adverse Effects   Methadone, a long-acting opioid, is used for the treatment of opioid dependence and as an analgesic. A French regional pharmacovigilance centre analysed, over a 10-year period, 509 reports of adverse effects in patients exposed to methadone, of which 8 out of 10 were serious. By being aware of the situations in which the use of methadone carries a risk of serious adverse effects, these situations can be anticipated. Full article available for download by subscribers 1 July 2024

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Mediator° trial appeal: a judgement that better reflects the harm done  Outlook   French appeal court finds Servier guilty of four charges, handing down sentences more respectful of the victims of decades of constant, organised deception. Full article available for download (free) 1 July 2024

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ New data after marketing authorisation: European Commission consultation  Advancing Healthcare Policy  Prescrire has contributed to a public consultation on the proposed revision of the rules governing variations to marketing authorisations, submitted to take into account new data, for example on efficacy or a new adverse effect. Full article available for download (free) 1 July 2024

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Non-comparative trials for marketing authorisations: EMA consultation  Advancing Healthcare Policy   Prescrire has contributed to a consultation on the use of non-comparative clinical trials to obtain marketing authorisation. Full article available for download (free) 1 July 2024

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Drug shortages: Prescrire calls for transparency  Advancing Healthcare Policy   In a joint letter to the European Commission, Prescrire, the European Public Health Alliance (EPHA) and France Assos Santé have called for medicine manufacturers and wholesalers to keep the EU's national drug regulatory agencies informed about stock levels. Full article available for download (free) 1 July 2024

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Enjoy these features, and more, in our upcoming issues COMING SOON• Selinexor in relapsed or refractory multiple myeloma  • Pseudoephedrine: a missed opportunity • Opioid replacement therapy during pregnancy • Prescrire's annual review of drug packaging  > Subscribe now 1 July 2024

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Covid-19: Follow Prescrire's independent, evidence-based analysis of the pandemic  COVID-19  Prescrire's editors are publishing an ongoing series of articles featuring independent analysis of developments related to the covid-19 pandemic. Useful and practical information, to help health professionals gain a clear and balanced view. 1 November 2023

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ New! "Top Texts of 2023", from the editors of Prescrire International  FREE SPECIAL EDITION  Check out this sampling of texts from Prescrire International, a wholly independent monthly drug bulletin, written by and for healthcare professionals. Inside, top articles from sections dedicated to new drugs authorised in Europe and key information on adverse drug effects, plus our annual update of drugs to avoid. > Click here for your free copy 1 August 2023

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Subscribe today for full access to top-quality content from Prescrire International  SUBSCRIBE NOW!  Enjoy access to subscriber-only content available on our website, including every article published in Prescrire International since 1992. Prices for a one-year subscription start at 165 euros (less for students and residents of lower-income countries). 1 January 2022

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Follow Prescrire International on Facebook and Twitter Keep up with the latest from Prescrire's editors, and support our values of independence and quality information, first and foremost in the interest of patients. Click here to > Follow us on Facebook or > Follow us on Twitter 1 January 2022

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Receive the free, monthly "Independent Drug & Healthcare Newsletter" Click here to sign up for the free Newsletter from the editors of the non-profit journal Prescrire International, with highlights of the contents of the latest issue. 1 July 2022

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Drugs to avoid, in the name of better patient care   DRUGS TO AVOID - 2024 UPDATE  Independent French medical journal Prescrire has published its annual update of drugs to avoid. The goal is to make it easier to choose high-quality care, and to prevent disproportionate harm to patients. > Read more

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Read more All the subjects in Prescrire's Spotlight >

• Sitemap |
• Terms of use |
• Contact
• |Top of page

---